NR1H4 and colitis: Gadaleta et al. (2011) demonstrated that activation of FXR by the selective agonist INT-747 can reduce the severity of DSS and TNBS-induced colitis in mice, leading to decreased production of the pro-inflammatory cytokine TNF-α in DCs [50].